German company BioNTech and pharmaceutical company Pfizer have sought authorization from the European Medicines Agency (EMA) to allow urgent use of their vaccine. Both companies have also sought authorization for use from the US Food and Drug Administration and the UK regulatory agency.
The vaccine of the German company BioNTech is 95% effective, according to the company, and in particular, is 94% effective in adults over the age of 65, who are among the most at risk groups from Covid.
"As a company located in the heart of Europe, today 's stage is important for us as we continue to seek to enable a worldwide supply of potential [vaccine] approval," said Ugur Sahin, CEO and Co - Founder and BioNTech.
The European Union recently signed an agreement to provide up to 300 million doses of the BioNTech and Pfizer vaccine.
Like the vaccine of the American company Moderna, this vaccine is built with mRNA technology, which helps the body recognize what is known as the "spike" protein of the coronavirus, which allows the virus to enter the body's cells. While other vaccines take genetic information from a virus and cultivate it in a human cell, the mRNA method simply requires the genetic code of the virus, thus shortening the production process.
Megjithatë, vaksina Pfizer/BioNTech duhet të ruhet në temperatura tepër të ftohta (-70 gradë Celcius) dhe infrastruktura për të cilën nuk ekziston në shumë vende, gjë që do të thotë se shumë shtete nuk kanë gjasa që të marrin këtë vaksinë.
Kjo është arsyeja që vaksina e Oksfordit, ndonëse më pak efektive se ajo e Pfizer/BioNTech dhe Moderna, u pa si më me shumë përparësi, për shkak se është e qëndrueshme në frigorifer, transportohet lehtë, mund të përdoret kudo në botë dhe është më e lirë.
Oxford / AstraZeneca has joined Covax, the program run by the World Health Organization to distribute vaccines to all countries and has entered into agreements with manufacturers in other countries, including our own. The Oxford vaccine was seen as the most suitable for developing countries. But for now, the Oxford vaccine is undergoing further testing after a manufacturing error was reported .
Recommended articles:
Sources: Guardian, Euronews, Entrepreneur
